RecruitingNot Applicable

To Evaluate the Safety of Autologous Tumor-infiltrating Lymphocytes(TILs) for the Treatment of Recurrent Ovarian Cancer

South Korea6 participantsStarted 2025-04-01

Plain-language summary

The objective of this clinical trial is to evaluate the safety of autologous tumor-infiltrating lymphocytes and to investigate their efficacy in recurrent ovarian cancer. Participants undergo the following process: There must be a cancerous lesion available for biopsy or surgery, and enhanced tumor-infiltrating lymphocytes are cultured from ovarian cancer tissue collected from the subject. These are processed into human cells for administration and injected into the subject.

Who can participate

Age range

20 Years

Sex

FEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Recurrent ovarian cancer * There is a cancerous lesion that can be removed by biopsy or surgery. Exclusion Criteria: * Patient with immunodeficiency or autoimmune diseases that may be exacerbated by immunotherapy * Patient deemed unsuitable by the principal investigator

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Since this trial has no assigned phase listed, what does that mean for how much is already known about the safety of this TIL cell therapy approach in ovarian cancer, and should that affect my decision?
2The trial involves lymphodepletion before the TIL infusion — which temporarily weakens the immune system — so how risky is that step given my current health, and what kind of monitoring would I have during that part of the process?
3High-dose IL-2 is known to have significant side effects in other treatments; can you walk me through what those side effects typically look like and how they would be managed if I were to participate in this trial?
4One of the main things this trial is measuring is whether the TIL cells can actually kill cancer cells in the lab — does that mean the researchers are still at an early stage of understanding whether this would work inside the body, and how does that compare to other treatment options I have right now?
5Because this requires my own tumor tissue to grow the TIL cells, would I need additional surgery or a procedure to collect that tissue, and is that something my current condition would allow?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Evaluation of cytotoxicity of cells against cancer cells

Timeframe: Treatment period- 2 months, follow-up- 4 months after completion of treatment

Evaluation of toxicity of protocol therapy including lymphodepletion, CHA-TIL, and high dose IL2

Timeframe: Treatment periods 2 months, follow-up 4 months after completion of treatment

Trial details

NCT IDNCT07651124

SponsorYong Wha Moon

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12-31

Contact for this trial

Yong Wha Moon

82-31-780-3436 ymoon@cha.ac.kr

View on ClinicalTrials.gov More Recurrent Ovarian Cancer trials